002688 Jinhe Biotechnology
- 4.55
- -0.10-2.15%
Jinhe Biotechnology News
Overview of the lifting of restrictions on A-shares | December 30
According to Zhichun Financial APP, on December 30, a total of 37 listed companies had their restricted shares unlocked, with a total market value of approximately 12.254 billion yuan. Today's specific situation of the restricted shares unlocked is as follows: Stock Abbreviation Stock Code Restricted Stock Type Number of Stocks Unlocked Henan Yuneng Holdings 001896 Placement of A-shares for original shareholders 0.205 billion Datang Telecom Technology 600198 Placement of A-shares for original shareholders 0.428 billion China National Software & Service 600536 Stock-based Incentive restricted circulation 0.7513 million Xiamen Tungsten 600549 Stock-based Incentive restricted circulation 3.6369 million Yueyang Forest & Paper 600963 Stock-based Incentive restricted circulation 0.27 million
Express News | Jinhe Biotechnology: Signed a Global Strategy cooperation agreement to jointly build an innovation platform with Shanghai Jiao Tong University.
Express News | jinhe biotechnology independent director, former senior vice chairman of the Zhengda Group, Yao Minpu, passed away.
Jinhe Biotechnology Includes Sheep, Lambs in Registration of Animal Diarrhea Medication
Express News | Jinhe Biotechnology: The company's application to change the registration of aureomycin premix veterinary drug products was approved by the Ministry of Agriculture.
Jinhe Biotech: Report for the third quarter of 2024
jinhe biotechnology (002688.SZ): Repurchase completed, cumulative expenditure of 50.0988 million yuan to repurchase 15.2215 million shares.
GeLongHui October 11th | Jinhe Biotechnology (002688.SZ) announced that as of October 10, 2024, the company has cumulatively repurchased 15.2215 million shares, accounting for 1.97% of the company's total share capital. The highest fill price was 5.16 yuan/share, and the lowest fill price was 2.92 yuan/share, with a total transaction amount of 50.0988 million yuan (excluding transaction costs). This buyback plan has been completed.
Express News | Jinhe Biotechnology: The company does not have any significant capital expenditure projects in the next few years.
Jinhe Biotech: 2024 Semi-Annual Report Summary
Jinhe Biotech: 2024 Semi-Annual Report
Jinhe Biotechnology (002688.SZ) released its semi-annual performance, with a net income of 91.0206 million yuan, a year-on-year increase of 1.86%.
Jinhe Biotechnology (002688.SZ) released its 2024 interim report, with a revenue of 1...
Jinhe Biotechnology (002688.SZ): Net income in the first half of the year was 91.0206 million yuan, a year-on-year increase of 1.86%.
On August 28th, Gelonhui reported its 2024 interim report, with a half-yearly revenue of 1.066 billion yuan, a year-on-year increase of 3.22%; the net income attributable to the shareholders of the listed company was 91.0206 million yuan, a year-on-year increase of 1.86%; the net income attributable to the shareholders of the listed company after deducting non-recurring gains and losses was 84.9487 million yuan, a year-on-year increase of 2.14%; and the basic earnings per share was 0.1166 yuan.
Jinhe Biotechnology (002688.SZ): Currently, there is no medication for treating monkeypox virus.
Jinhe Biotechnology (002688.SZ) stated on the investor platform on August 21 that the company invested in Yunnan Rueitai Biological Products Co., Ltd., a subsidiary of Jinhe Youben. The company has CE-certified testing reagents for monkey-pox virus using nucleic acid POCT fluorescence method. The company currently does not have drugs to treat monkeypox virus.
Jinhe Biotechnology (002688.SZ): granted 11.75 million stock options to 25 incentive recipients.
On August 12th, Gelunhui reported that Jinhe Biotechnology (002688.SZ) held the 16th meeting of the sixth board of directors on August 12th, 2024 to review and approve the "Proposal on Granting Stock Options to the Incentive Objects in the 2024 Stock Option Incentive Plan". The company's board of directors believes that the granting conditions for the stock options stipulated in the "2024 Stock Option Incentive Plan of Jinhe Biotechnology Co., Ltd." have been achieved, and agrees to authorize the granting of 11.75 million stock options to 25 eligible incentive objects on August 12th, 2024 at an exercise price of 2.94 yuan per share.
Express News | Jinhe Biotechnology: the market share of its subsidiary's pharmaceutical products in the USA is gradually expanding.
Jinhe Biotechnology (002688.SZ): Has repurchased 1.97% of its shares.
Jinhe Biotechnology (002688.SZ) announced on August 1 that, as of July 31, 2024, the company has cumulatively repurchased 15,221,500 shares of the company through a repurchase special securities account in a centralized bidding trading method, accounting for 1.97% of the total share capital of the company. The highest fill price was 5.16 yuan/share and the lowest fill price was 2.92 yuan/share, with a total transaction amount of 50,098,780.21 yuan (excluding transaction fees). This share repurchase complies with the company's established share repurchase plan and relevant laws and regulations.
Jinhe Biotechnology (002688.SZ): the African swine fever gene-deficient freeze-dried inactivated vaccine is currently in the review stage of the Ministry of Agriculture and Rural Affairs.
Jinhe Biotechnology (002688.SZ) stated on the investor interaction platform on July 25 that the African swine fever gene-deficient lyophilized inactivated vaccine, which is jointly developed and applied by the company and a well-known domestic enterprise, is currently in the review stage of the Ministry of Agriculture and Rural Affairs.
Jinhe Biotechnology (002688.SZ) plans to launch 11.75 million stock option incentive plans.
On July 19th, Gelonhui announced that Jinhe Biotechnology (002688.SZ) has released its 2024 stock option incentive plan. The plan is expected to grant a total of 11.75 million stock options to incentive recipients, accounting for about 1.52% of the company's total share capital of 771,694,398 shares on the day the incentive plan draft was announced. The incentive plan involves a total of 25 recipients, with an exercise price of 2.94 yuan per share option.
Express News | Jinhe Biotechnology: jointly established Zhongnong Jinhe Youben Chengdu Research Institute Co., Ltd. and signed a cooperation agreement.
Jinhe Biotechnology (002688.SZ): repurchased 1.95% of shares.
Jinhe Biotechnology (002688.SZ) announced on July 1 that as of June 30, 2024, the company had repurchased 15,221,500 shares through a repurchase dedicated securities account through centralized bidding trading, accounting for 1.95% of the total share capital of the company. The highest fill price was 5.16 yuan/share, and the lowest fill price was 2.92 yuan/share. The total trading amount was CNY 50,098,780.21 (excluding transaction fees). The share repurchase this time meets the company's established share repurchase plan and relevant laws and regulations.
No Data